Talbot Financial’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-428,087
Closed -$10.4M 69
2025
Q2
$10.4M Buy
428,087
+98,613
+30% +$2.3M 0.98% 41
2025
Q1
$8.35M Buy
329,474
+10,520
+3% +$275K 1.05% 40
2024
Q4
$8.46M Buy
318,954
+13,752
+5% +$373K 1.01% 39
2024
Q3
$8.83M Buy
305,202
+10,735
+4% +$313K 1.08% 38
2024
Q2
$8.24M Buy
294,467
+1,234
+0.4% +$34K 1.06% 37
2024
Q1
$8.14M Buy
293,233
+29,725
+11% +$825K 1.09% 39
2023
Q4
$7.59M Buy
263,508
+6,849
+3% +$207K 1.14% 36
2023
Q3
$8.51M Buy
256,659
+10,596
+4% +$375K 1.48% 26
2023
Q2
$9.03M Buy
246,063
+2,899
+1% +$113K 1.54% 21
2023
Q1
$9.92M Buy
243,164
+3,240
+1% +$140K 1.84% 17
2022
Q4
$12.3M Buy
+239,924
New +$11.5M 2.53% 10

Other funds holding PFE

Talbot Financial's PFE Position: Q3 2025 in Review

Talbot Financial sold out of Pfizer (PFE) in Q3 2025, closing a stake of 428,087 shares — an estimated $10.4M sold.

Talbot Financial first reported a position in PFE in Q4 2022 and held it in 11 quarters. The position peaked at $12.3M in Q4 2022. 2,812 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Talbot Financial reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • Talbot Financial sold 428,087 Pfizer shares in Q3 2025, an estimated $10.4M.
  • Talbot Financial first reported a position in Pfizer in Q4 2022 and held it in 11 quarters.
  • Talbot Financial's Pfizer position peaked at $12.3M in Q4 2022.
  • 2,812 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Talbot Financial's 13F filing for Q3 2025, filed 8 Oct 2025.